Introduction: Cervical cancer is a malignant neoplasm affecting the lower portion of the uterus, usually associated with persistent infection by the human papillomavirus (HPV). In Brazil, it ranks as the third most common cancer among women, with an estimated 17,010 new cases per year between 2023 and 2025, corresponding to a rate of 15.38 per 100,000. Incidence is even higher in the North (20.48/100,000) and Northeast (17.59/100,000) regions, ranking second and third in frequency, respectively. Despite being preventable through vaccination and screening, it remains a significant cause of hospitalizations and deaths, especially among socially vulnerable women, with increased severity in those over 50 years of age. Thus, understanding its distribution is essential to guide intervention strategies. Objectives: To describe the epidemiological profile of hospital admissions due to cervical cancer in Brazil between 2015 and 2024. Methods: This is an ecological, descriptive study using secondary data from the SUS Hospital Information System (SIH/SUS) for the period 2015 to 2024. Variables analyzed included number of hospitalizations, deaths, age group, race/ethnicity, geographic location, year of registration, and costs. Results: Between 2015 and 2024, there were 237,963 hospitalizations and 2,949 deaths. The Southeast region accounted for the majority of cases (39.53% | 94,090), while the Center-West had the lowest proportion (7.29% | 17,348). The most affected age group was 35 to 49 years (40.66% | 96,776). In terms of race/ethnicity, most cases were among mixed-race (parda) women (45.77% | 108,925), followed by white and black women; Indigenous women accounted for only 0.14% (343). The year 2024 had the highest number of hospitalizations (12.89% | 30,676) and deaths (11.20% | 2,660). The Northeast led in hospital costs (R$ 167,151,701.37 | 33.58%), followed by the Southeast, while the North had the lowest share (R$ 31,815,400.12 | 6.50%). The state of Pará alone accounted for R$ 14,214,376.65 (44.67% of the North's expenses). Despite having fewer total cases, the North had the highest mortality rate (15.73 per 100,000), exceeding the national average (11.06/100,000), indicating potential barriers to early diagnosis and timely treatment. Conclusion: The findings highlight significant disparities in the incidence and costs associated with cervical cancer in Brazil. The high concentration of cases among mixed-race women reflects social inequities and barriers to preventive care. The increase in cases and deaths in 2024 reinforces the urgency of expanding vaccination, screening, and continuous care, with a focus on the most vulnerable regions.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
